Patent: 10,022,427
✉ Email this page to a colleague
Summary for Patent: 10,022,427
| Title: | Interferon lambda-antibody complexes |
| Abstract: | The present invention concerns methods and compositions for forming complexes of interferon-.lamda. with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-.lamda. and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer\'s disease, multiple sclerosis or viral infection than interferon-.lamda. alone, antibody alone, or the combination of unconjugated interferon-.lamda. and antibody. |
| Inventor(s): | Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Liu; Donglin (Kendall Park, NJ) |
| Assignee: | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) |
| Application Number: | 14/997,843 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,022,427
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2028-04-10 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2028-04-10 |
| Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2028-04-10 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2028-04-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
